CA-TYLIN
16.5.2022 16:02:14 CEST | Business Wire | Press release
The GPO Group and Sam Schwartz, one of its operating companies, as part of a global effort to enhance connections and collaboration among companies in the Dar Group’s Global Infrastructure (GI) Pillar, are formally aligning with TYLin, the leading brand in the GI Pillar.
The GPO Group and Sam Schwartz have added a TYLin “unifier” line to their names. Effective immediately, GPO will be known as GPO, A TYLin Company. Similarly, Sam Schwartz will be known as Sam Schwartz, A TYLin Company.
The addition of the unifier line is part of a global strategic initiative to unify the companies in the Dar Group GI Pillar under the TYLin brand to provide more efficient access to its vast global resources and promote better collaboration among its staff. Aligning the two companies with TYLin — particularly in the rail and transit segments — means that GPO and Sam Schwartz, transportation and mobility leaders in Europe and the Americas, respectively, will expand their ability to deliver innovative thinking and practical implementation across all aspects of physical and digital mobility networks.
“By strategically aligning TYLin, GPO and Sam Schwartz we will strengthen or ability to provide innovative solutions based on real-world insights from around the globe,” said Matthew Cummings, President, and Chief Executive Officer, TYLin. “This alignment will ultimately help us achieve our shared goal of developing smarter cities and connecting communities.”
“Aligning with the TYLin brand complements and expands our presence and technical expertise in Europe and in the Americas and will allow us to connect our people, places and ideas more efficiently to meet our clients’ evolving needs around the world,” said Xavier Montobbio, President, and Chief Executive Officer of the GPO Group. “This effort to enhance collaboration and connections is embodied in the addition of the ‘unifier’ line to the GPO and Sam Schwartz company names.”
Earlier this year, TYLin launched a brand strategy to unify its global operations. The unified brand connects clients more effectively with TYLin’s multi-discipline global engineering resources to solve infrastructure challenges with innovative solutions at the regional and local levels in the Aviation; Bridge; Buildings; Ports + Marine; Rail + Transit; Roads + Highways; and Water sectors.
About Dar Group
Dar Group is a privately owned international network of professional services firms with over 17,670 employees in 297 offices across over 100 countries. Dar Group is dedicated to the planning, design, engineering and project management of facilities, installations and structures that elevate the sustainable advancement of communities worldwide. For more information, visit www.dargroup.com .
About TYLin
Founded in 1954, TYLin is a globally recognized, full-service infrastructure consulting firm committed to providing innovative, cost-effective, constructible designs for the global infrastructure market. With 3,200 employees working in 65 offices throughout the Americas, Asia, and Europe, the firm provides support on projects of varying size and complexity. TYLin is a member of Dar Group, a global, privately-owned professional services group, and its industry-leading family of Global Infrastructure companies. For more information about the company, please visit www.tylin.com .
About GPO Group
Founded in 1985, GPO Group is a global group specialized in mobility, railway consulting & engineering that renders planning, design, construction, and operational services in the mobility & transportation industries. GPO Group established a strategic partnership with Dar Group in 2017, which connected us with an international first-rate professional network. Sam Schwartz has been part of GPO Group since 2015. For more information visit www.gpogroup.com .
About Sam Schwartz
Since 1995, Sam Schwartz has been known as the transportation engineering, planning, and consulting firm that solves the industry’s most challenging problems by combining technical expertise with creative approaches. Headquartered in New York, the firm has teams of professional across disciplines including transportation and environmental planning; transit; civil engineering; and community engagement. For more information, visit www.samschwartz.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005325/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom